Kim HS, Kim HJ, Hong ES, et al. - In Korean patients with vitiligo, researchers quantified the incidence of melanoma and nonmelanoma skin cancer (NMSC) and compared it with matched nonvitiligo controls. A retrospective matched cohort study was conducted with 131,245 cases of incident vitiligo and 2,624,900 age- and gender-matched (1:20) controls at index date selected from the Korean National Health Insurance database between January 2005 and December 2017. Vitiligo patients were followed up for a mean duration of 6·34 years vs a follow-up period of 6·27 years for matched controls. Data reported that ultraviolet (UV) treatment-adjusted HR for melanoma in vitiligo patients was 3·32 and 1·29 for NMSC. The HRs for melanoma and NMSC were 3·37 and 1·35, respectively, in the vitiligo population without a history of UV treatment. Investigators found that the risk of skin cancer was increased in the Korean vitiligo population in contrast to white patients with vitiligo. It is noteworthy, however, that in Korean vitiligo patients the incidence of skin cancer was lower than that of their white counterparts. Skin cancer surveillance in the vitiligo population may be adjusted for the race due to possible ethnic differences in the susceptibility to skin cancer.